Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions. 

Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.

CEO Adrian Rawcliffe talked with Scrip about filing and early commercial plans for afami-cel in synovial carcinoma if it is approved by the FDA.

The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.